Literature DB >> 11281373

The role of the insulin-like growth factor system in adrenocortical tumourigenesis.

M M Weber1, C Fottner, E Wolf.   

Abstract

BACKGROUND: The insulin-like growth factor (IGF) system plays a central role in the mechanism of transformation and tumourigenesis. Elevated levels of IGF-II and IGF-I have been found in adrenocortical carcinomas.
MATERIAL AND METHODS: We examined binding characteristics and concentrations of both IGF-receptors in normal adult human adrenocortical glands, and compared them with the IGF-I receptor binding in adrenocortical rumours of various origins. The human IGF-I receptor was overexpressed in the mouse adrenocortical tumour cell line Y1, and growth studied in response to IGF stimulation. The influence of IGF-II on adrenal morphology and function was assessed in transgenic mice that postnatally overexpress IGF-II.
RESULTS: While the abundance of the IGF-I receptor in adrenocortical hyperplasias and adenomas was similar to normal tissue, a strong overexpression of the intact IGF-I receptor was found in three out of four adrenocortical carcinomas. Y1 cells overexpressing the human IGF-I receptor respond to IGF-I with an increase in thymidine incorporation by 140%. Furthermore, the antiproliferative effect of ACTH is blunted. In transgenic mice postnatally overexpressing IGF-II, adrenal weight is increased, mainly due to a 50% increase in the number of zona fasciculata cells. Plasma corticosterone levels in these mice are twofold higher than in controls, in contrast to similar plasma ACTH levels, thus indicating a direct effect of IGF-II on adrenal cell hyperplasia and function.
CONCLUSION: There is substantial evidence that the IGF-system is involved in adrenal growth and tumourigenesis. High local levels of IGF-II in combination with elevated IGF-I receptor concentrations would represent a significant growth advantage of the adrenocortical carcinoma cell and could contribute to a highly malignant phenotype. IGF-II overexpression alone seems not to be sufficient for malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11281373     DOI: 10.1046/j.1365-2362.2000.0300s3069.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  9 in total

Review 1.  Review paper: origin and molecular pathology of adrenocortical neoplasms.

Authors:  M Bielinska; H Parviainen; S Kiiveri; M Heikinheimo; D B Wilson
Journal:  Vet Pathol       Date:  2009-03       Impact factor: 2.221

Review 2.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 3.  Current and emerging therapies for advanced adrenocortical carcinoma.

Authors:  Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu
Journal:  Oncologist       Date:  2011-01-06

4.  Virilising adrenocortical tumours in children.

Authors:  Walter Bonfig; Iris Bittmann; Susanne Bechtold; Birgit Kammer; Vera Noelle; Sissi Arleth; Klemens Raile; Hans-Peter Schwarz
Journal:  Eur J Pediatr       Date:  2003-06-14       Impact factor: 3.183

Review 5.  Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas.

Authors:  Thomas J Giordano
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

6.  Assessment of the role of transcript for GATA-4 as a marker of unfavorable outcome in human adrenocortical neoplasms.

Authors:  Angela S Barbosa; Luciano R Giacaglia; Regina M Martin; Berenice B Mendonca; Chin J Lin
Journal:  BMC Endocr Disord       Date:  2004-07-07       Impact factor: 2.763

7.  The impact of the IGF-1 system of cancer cells on radiation response - An in vitro study.

Authors:  Senthiladipan Venkatachalam; Esther Mettler; Christian Fottner; Matthias Miederer; Bernd Kaina; Matthias M Weber
Journal:  Clin Transl Radiat Oncol       Date:  2017-10-05

8.  The insulin and igf-I pathway in endocrine glands carcinogenesis.

Authors:  Roberta Malaguarnera; Alaide Morcavallo; Antonino Belfiore
Journal:  J Oncol       Date:  2012-08-08       Impact factor: 4.375

9.  IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.

Authors:  Marine Guillaud-Bataille; Bruno Ragazzon; Aurélien de Reyniès; Claire Chevalier; Isabelle Francillard; Olivia Barreau; Virginie Steunou; Johann Guillemot; Frédérique Tissier; Marthe Rizk-Rabin; Fernande René-Corail; Abir Al Ghuzlan; Guillaume Assié; Xavier Bertagna; Eric Baudin; Yves Le Bouc; Jérôme Bertherat; Eric Clauser
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.